Vaxneuvance
Vaxneuvance is an originator product from MSD Merck Sharp & Dohme AG and is listed on the FOPH Specialities List. Swiss mandatory health insurance therefore reimburses it within the authorised indication. The public price ranges from CHF 77.95 to CHF 631.55 depending on the pack; the patient co-payment is 10 per cent plus the deductible.
Core data
- Authorisation holder
- MSD Merck Sharp & Dohme AG
- ATC code
- J07AL02
- IT group
- 08.08 Impfstoffe
- Active substances
- Vaccinum pneumococcale polysaccharidicum CRM conjugatum 15-valens
- Preparation type
- Originator product
- On the SL since
- 01/04/2023
- Last price change
- 01/12/2025
- Co-payment
- 10%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Inj Susp | Fertspr 0.5 ml | CHF 56.56 | CHF 77.95 | 01/04/2023 | B | 7680687520010 |
| Inj Susp | 10 Fertspr 0.5 ml | CHF 565.61 | CHF 631.55 | 01/05/2024 | B | 7680687520027 |
Limitation
This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.
The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.
Kostenübernahme bei Personen ab 65 Jahren.
Die Preise der Impfstoffe sind Höchstpreise (Art. 52 Abs. 3 KVG) und kommen bei Reihenimpfungen (z.B. im schulärztlichen Dienst) nicht zur Anwendung. In diesen Fällen gelten die von den Krankenversicherern mit den zuständigen Behörden ausgehandelten bzw. die allenfalls von den Behörden festgesetzten Tarife. Wenn der Impfstoff zu einem günstigeren Preis bezogen wird (z.B. im Rahmen von Reihenimpfungen), darf der Arzt oder die Ärztin nicht den Publikumspreis der SL verrechnen.
Die Vergünstigung muss gemäss Artikel 56 Absatz 3 KVG weitergegeben werden, ausser es bestehen Vereinbarungen nach Artikel 56 Absatz 3bis KVG.
More preparations in this group
FAQ
Is Vaxneuvance covered by Swiss health insurance?
Yes, but only under conditions. Vaxneuvance is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.
What does Vaxneuvance cost in Switzerland?
The public price is the maximum price set by the FOPH and for Vaxneuvance ranges from CHF 77.95 to CHF 631.55 per pack. The ex-factory price ranges from CHF 56.56 to CHF 565.61. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages